Evidence map›Paper›PMID 26502922›Full record

ArticleBMC gastroenterology2015

Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.

Constantinos Giaginis, Christos Damaskos, Ioannis Koutsounas, Adamantia Zizi-Serbetzoglou, Nicolaos Tsoukalas, Efstratios Patsouris, Gregorios Kouraklis, Stamatios Theocharis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 54 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Constantinos GiaginisFirst Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. cgiaginis@aegean.gr.
Christos DamaskosSecond Department of Propedeutic Surgery, Medical School, University of Athens, Athens, Greece.
Ioannis KoutsounasFirst Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Adamantia Zizi-SerbetzoglouDepartment of Pathology, Tzaneio General Hospital, Piraeus, Greece.
Nicolaos TsoukalasFirst Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Efstratios PatsourisFirst Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Gregorios KouraklisSecond Department of Propedeutic Surgery, Medical School, University of Athens, Athens, Greece.
Stamatios TheocharisFirst Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GRTzaneion General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHistone deacetylases (HDACs) have been associated with malignant tumor development and progression in humans. HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical trials. The present study aimed to evaluate the clinical significance of HDAC-1, -2, -4 and -6 protein expression in pancreatic adenocarcinoma.

methodsHDAC-1, -2, -4 and -6 protein expression was assessed immunohistochemically on 70 pancreatic adenocarcinoma tissue specimens and was statistically analyzed with clinicopathological characteristics and patients' survival.

resultsEnhanced HDAC-1 expression was significantly associated with increased tumor proliferative capacity (p = 0.0238) and borderline with the absence of lymph node metastases (p = 0.0632). Elevated HDAC-4 expression was significantly associated with the absence of organ metastases (p = 0.0453) and borderline with the absence of lymph node metastases (p = 0.0571) and tumor proliferative capacity (p = 0.0576). Enhanced HDAC-6 expression was significantly associated with earlier histopathological stage (p = 0.0115) and borderline with smaller tumor size (p = 0.0864). Pancreatic adenocarcinoma patients with enhanced HDAC-1 and -6 expression showed significantly longer survival times compared to those with low expression (p = 0.0022 and p = 0.0113, respectively), while a borderline association concerning HDAC-2 expression was noted (p = 0.0634).

conclusionsThe present study suggested that HDACs may be implicated in pancreatic malignant disease progression, being considered of clinical utility with potential use as therapeutic targets.

Indexed as

Gene ExpressionAdenocarcinomaAgedBiomarkers, TumorCell ProliferationFemaleHistone Deacetylase 1Histone Deacetylase 2Histone Deacetylase 6Histone DeacetylasesHumansMaleMiddle AgedNeoplasm MetastasisPancreatic NeoplasmsRepressor ProteinsBiomarkers, TumorHDAC1 protein, humanHDAC2 protein, humanHDAC4 protein, humanHDAC6 protein, humanHistone Deacetylase 1Histone Deacetylase 2Histone Deacetylase 6Histone DeacetylasesRepressor Proteins

Identifiers

PMID26502922
PMCPMC4621854
OpenAlexW1832171986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.